ARS Pharmaceuticals Inc (NASDAQ:SPRY) has a beta value of 0.86 and has seen 1.51 million shares traded in the last trading session. The company, currently valued at $1.23B, closed the last trade at $12.53 per share which meant it lost -$0.05 on the day or -0.40% during that session. The SPRY stock price is -47.73% off its 52-week high price of $18.51 and 39.74% above the 52-week low of $7.55. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.89 million shares traded. The 3-month trading volume is 1.57 million shares.
The consensus among analysts is that ARS Pharmaceuticals Inc (SPRY) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 4 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight.
ARS Pharmaceuticals Inc (NASDAQ:SPRY) trade information
Sporting -0.40% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the SPRY stock price touched $12.53 or saw a rise of 5.08%. Year-to-date, ARS Pharmaceuticals Inc shares have moved 18.77%, while the 5-day performance has seen it change -4.71%. Over the past 30 days, the shares of ARS Pharmaceuticals Inc (NASDAQ:SPRY) have changed 23.08%. Short interest in the company has seen 19.43 million shares shorted with days to cover at 15.06.
Wall Street analysts have a consensus price target for the stock at $22, which means that the shares’ value could jump 43.05% from current levels. The projected low price target is $18.0 while the price target rests at a high of $30.0. In that case, then, we find that the current price level is -139.43% off the targeted high while a plunge would see the stock gain -43.66% from current levels.
ARS Pharmaceuticals Inc (SPRY) estimates and forecasts
The company’s shares have lost -12.50% over the past 6 months.
Earnings growth for 2025 is a modest -1764.10% while over the next 5 years, the company’s earnings are expected to increase by 43.97%.
SPRY Dividends
ARS Pharmaceuticals Inc is expected to release its next earnings report on 2025-Mar-19 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
ARS Pharmaceuticals Inc (NASDAQ:SPRY)’s Major holders
Insiders own 22.97% of the company shares, while shares held by institutions stand at 74.91% with a share float percentage of 97.25%. Investors are also buoyed by the number of investors in a company, with ARS Pharmaceuticals Inc having a total of 229.0 institutions that hold shares in the company. The top two institutional holders are DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) with over 11.08 million shares worth more than $94.27 million. As of 2024-06-30, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) held 11.4409% of shares outstanding.
The other major institutional holder is RA CAPITAL MANAGEMENT, L.P., with the holding of over 10.86 million shares as of 2024-06-30. The firm’s total holdings are worth over $92.43 million and represent 11.2168% of shares outstanding.
